Quantum BioPharma Ltd. QNTM

Annual Quarterly

No annual revenue total was found in Quantum BioPharma Ltd.'s SEC filings.

Quantum BioPharma Ltd. (QNTM) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Dec 31, 2025 it held $1.9 million in cash and investments and $1.4 million in total debt.

Revenue
—
Net income
$-23.61M
+33.1% vs prior year
Operating cash flow
$-8.24M
-19.8% vs prior year
Free cash flow
$-6.88M
+36.5% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
12
-83.3% vs prior year
Net cash
$501,643
FY 2025
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
QNTM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Ontario, Canada
Headquarters
Toronto
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1771885
Former names
FSD Pharma Inc. (until Aug 15, 2024)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Operating income
-$27.4M
-$33.7M
-$30.7M
Net income
-$23.6M
-$35.3M
-$31.8M
Operating cash flow
-$28.3M
-$20.7M
-$19.1M
Free cash flow
-$28.4M
—
—
Total assets
$38.4M
$63.0M
$42.0M
Total liabilities
$7.9M
$8.8M
$5.7M
Stockholders' equity
$30.5M
$54.1M
$36.3M
Cash and investments
$17.0M
$35.3M
$17.5M
Total debt
$215,874
$255,356
$125,962

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Oct 8, 2026 Oct 8, 2026
6-K Current report (foreign issuer) Oct 6, 2026 Oct 6, 2026
6-K Current report (foreign issuer) Sep 24, 2026 Sep 24, 2026
6-K Current report (foreign issuer) Sep 17, 2026 Sep 17, 2026
6-K Current report (foreign issuer) Sep 17, 2026 Sep 17, 2026
6-K Current report (foreign issuer) Sep 15, 2026 Sep 15, 2026

All 356 Quantum BioPharma Ltd. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.